登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IL23A & IL12B >ILB-H5219

Human IL-23 alpha & IL-12 beta Heterodimer Protein, premium grade

分子别名(Synonym)

IL-23 alpha & IL-12 beta

表达区间及表达系统(Source)

Human IL-23A&IL-12B Heterodimer Protein, premium grade (ILB-H5219) is expressed from human 293 cells (HEK293). It contains AA Ile 23 - Ser 328 (IL-12B) & Arg 20 - Pro 189 (IL-23A) (Accession # P29460-1 (IL-12B) & Q9NPF7-1 (IL-23A)).

Predicted N-terminus: Ile 23

Human IL-23A&IL-12B Heterodimer Protein, premium grade (ILB-H5219), designed for preclinical stage, has the same activity and performance with GMP Human IL-23A&IL-12B Heterodimer Protein, which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.

Request for sequence

蛋白结构(Molecular Characterization)

This protein carries no "tag"

The protein has a calculated MW of 55.0 kDa. The protein migrates as 60-65 kDa and 116 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

无菌(Sterility)

The sterility testing was performed by membrane filtration method.

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

IL23A & IL12B SDS-PAGE

Human IL-23A&IL-12B Heterodimer Protein, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

IL23A & IL12B ELISA

Immobilized Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human IL23A&IL12B P40 domain Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

IL23A & IL12B ELISA

Immobilized Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) at 5 μg/mL (100 μL/well) can bind Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) with a linear range of 1-20 (Routinely tested).

Protocol

IL23A & IL12B ELISA

Immobilized Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) at 2 μg/mL (100 μL/well) can bind Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) with a linear range of 0.1-6 ng/mL (Routinely tested).

Protocol

 

背景(Background)

Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IL23A & IL12B靶点信息
英文全称:Interleukin-23
中文全称:白细胞介素-23复合体
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:15详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定